Cargando…
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis
Coccidioides spp. are important pathogens in regions where they are endemic, and new treatment options are needed. Here, isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. B...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316117/ https://www.ncbi.nlm.nih.gov/pubmed/33782009 http://dx.doi.org/10.1128/AAC.02344-20 |
_version_ | 1783729814874619904 |
---|---|
author | Kovanda, Laura L. Sass, Gabriele Martinez, Marife Clemons, Karl V. Nazik, Hasan Kitt, Therese M. Wiederhold, Nathan Hope, William W. Stevens, David A. |
author_facet | Kovanda, Laura L. Sass, Gabriele Martinez, Marife Clemons, Karl V. Nazik, Hasan Kitt, Therese M. Wiederhold, Nathan Hope, William W. Stevens, David A. |
author_sort | Kovanda, Laura L. |
collection | PubMed |
description | Coccidioides spp. are important pathogens in regions where they are endemic, and new treatment options are needed. Here, isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. Broth macrodilution was performed on Coccidioides isolates to measure minimal effective concentrations (MEC) and minimal fungicidal concentrations (MFC). Mice were inoculated with Coccidioides posadasii (Silveira strain). Treatment started 4 days postinoculation. In model 1, mice were treated for 19 days, followed by 30 days of off-therapy observation, measuring survival through day 49 and residual fungal burden. Treatments included ISAVUSULF (prodrug; 186, 279, or 372 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Model 2 included 7-day treatment with ISAVUSULF (prodrug; 74.4, 111.6, or 148.8 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Serial plasma and tissues samples were obtained for pharmacokinetics (PK) and fungal burden measurement, respectively. Fifty percent minimal effective concentration (MEC(50)) values were 0.39 mg/liter (isavuconazole [ISAV]) and 12.5 mg/liter (FLU). Treatment with ISAVUSULF186 or with either FLU dose resulted in higher survival compared to that in the untreated group. Treatment with ISAVUSULF186 or ISAVUSULF279 twice daily or FLU100 reduced fungal burden in all organs (model 1). In model 2, a >1 log(10) CFU/organ reduction was demonstrated, with ISAV area under the concentration-time curve (AUC) values achieved with 111.6 mg/kg twice daily (56.8 mg · h/liter) in the spleen and liver. FLU AUC values of 100 and 500 mg·h/liter for 20 and 100 mg/kg doses, respectively, resulted in a >1 log(10) CFU/organ mean reduction in all organs. ISAVUSULF and FLU improved survival and reduced fungal burden. Increasing plasma drug exposures resulted in decreases in fungal burden. |
format | Online Article Text |
id | pubmed-8316117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-83161172021-11-18 Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis Kovanda, Laura L. Sass, Gabriele Martinez, Marife Clemons, Karl V. Nazik, Hasan Kitt, Therese M. Wiederhold, Nathan Hope, William W. Stevens, David A. Antimicrob Agents Chemother Pharmacology Coccidioides spp. are important pathogens in regions where they are endemic, and new treatment options are needed. Here, isavuconazonium sulfate (ISAVUSULF) and fluconazole (FLU) were evaluated in experimental disseminated coccidioidomycosis to characterize drug exposures associated with efficacy. Broth macrodilution was performed on Coccidioides isolates to measure minimal effective concentrations (MEC) and minimal fungicidal concentrations (MFC). Mice were inoculated with Coccidioides posadasii (Silveira strain). Treatment started 4 days postinoculation. In model 1, mice were treated for 19 days, followed by 30 days of off-therapy observation, measuring survival through day 49 and residual fungal burden. Treatments included ISAVUSULF (prodrug; 186, 279, or 372 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Model 2 included 7-day treatment with ISAVUSULF (prodrug; 74.4, 111.6, or 148.8 mg/kg twice daily), FLU (20 or 100 mg/kg once daily), and no treatment. Serial plasma and tissues samples were obtained for pharmacokinetics (PK) and fungal burden measurement, respectively. Fifty percent minimal effective concentration (MEC(50)) values were 0.39 mg/liter (isavuconazole [ISAV]) and 12.5 mg/liter (FLU). Treatment with ISAVUSULF186 or with either FLU dose resulted in higher survival compared to that in the untreated group. Treatment with ISAVUSULF186 or ISAVUSULF279 twice daily or FLU100 reduced fungal burden in all organs (model 1). In model 2, a >1 log(10) CFU/organ reduction was demonstrated, with ISAV area under the concentration-time curve (AUC) values achieved with 111.6 mg/kg twice daily (56.8 mg · h/liter) in the spleen and liver. FLU AUC values of 100 and 500 mg·h/liter for 20 and 100 mg/kg doses, respectively, resulted in a >1 log(10) CFU/organ mean reduction in all organs. ISAVUSULF and FLU improved survival and reduced fungal burden. Increasing plasma drug exposures resulted in decreases in fungal burden. American Society for Microbiology 2021-05-18 /pmc/articles/PMC8316117/ /pubmed/33782009 http://dx.doi.org/10.1128/AAC.02344-20 Text en Copyright © 2021 Kovanda et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Pharmacology Kovanda, Laura L. Sass, Gabriele Martinez, Marife Clemons, Karl V. Nazik, Hasan Kitt, Therese M. Wiederhold, Nathan Hope, William W. Stevens, David A. Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title_full | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title_fullStr | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title_full_unstemmed | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title_short | Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis |
title_sort | efficacy and associated drug exposures of isavuconazole and fluconazole in an experimental model of coccidioidomycosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316117/ https://www.ncbi.nlm.nih.gov/pubmed/33782009 http://dx.doi.org/10.1128/AAC.02344-20 |
work_keys_str_mv | AT kovandalaural efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT sassgabriele efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT martinezmarife efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT clemonskarlv efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT nazikhasan efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT kitttheresem efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT wiederholdnathan efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT hopewilliamw efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis AT stevensdavida efficacyandassociateddrugexposuresofisavuconazoleandfluconazoleinanexperimentalmodelofcoccidioidomycosis |